Megha Prasad, MD
Cardiovascular Disease · New York, NYNPI 1174887137
Payments from drug & device makers
Across 694 payments — averaging $1216.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$177K
- Abbott$124K
- Boehringer Ingelheim$119K
- Medtronic$112K
- ZOLL Circulation Inc$66K
- Shockwave Medical, Inc$55K
- plus $192K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 109 | $176,914 |
| Abbott | 53 | $123,627 |
| Boehringer Ingelheim | 111 | $118,704 |
| Medtronic(2 entities) | 148 | $111,709 |
| ZOLL Circulation Inc | 14 | $66,232 |
| Shockwave Medical, Inc | 11 | $55,287 |
| Boston Scientific | 68 | $49,051 |
| Janssen Research & Development, LLC | 8 | $30,786 |
| Lilly USA, LLC | 16 | $21,759 |
| Cathworks, Inc. | 8 | $18,471 |
| Terumo Medical Corporation | 18 | $13,234 |
| Abiomed | 19 | $13,014 |
| Biotronik Inc. | 21 | $12,010 |
| Neovasc Medical Inc | 6 | $11,929 |
| Spectrawave, Inc | 4 | $9,844 |
| AstraZeneca | 9 | $3,541 |
| Philips North America LLC | 11 | $2,964 |
| GE HealthCare | 2 | $2,216 |
| Novartis | 14 | $422 |
| Cardiovascular Systems Inc. | 5 | $396 |
| Cardinal Health 200 LLC | 11 | $314 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $290 |
| Cardiva Medical, Inc. | 1 | $278 |
| Asahi Intecc USA, Inc. | 4 | $139 |
| Heartflow, Inc. | 1 | $131 |
| Regeneron | 1 | $130 |
| Amgen | 6 | $126 |
| Pfizer | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $113 |
| Teleflex LLC | 1 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Angiodynamics, Inc. | 1 | $47 |
| Johnson & Johnson | 2 | $40 |
| Edwards Lifesciences | 1 | $38 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
How this compares
$844,030 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.